Filing summary
Entity and period: The supplied filing is Point Capital, Inc.’s Form 10-K for the fiscal year ended December 31, 2018, filed April 4, 2019. This does not match the request metadata naming Silo Pharma, Inc.; the filing reports annual results, not a standalone fourth quarter.
Business context
Point Capital shifted from a business development company/investment company to an apparel-development business effective September 29, 2018, after acquiring NFID brand assets. The assets included trademarks, a website, designs and samples, and a brand ambassador agreement; consideration was 2,000,000 common shares valued at $152,235. The company planned a direct-to-consumer streetwear launch and stated NFID.com was expected to launch in the second quarter of 2019. It had no employees, and its CEO worked part-time.
Financial performance and position
| Metric | 2018 | 2017 |
|---|---|---|
| Revenue | $0 | $0 |
| Operating expenses | $594,242 | $490,871 |
| Loss from operations | $(594,242) | $(490,871) |
| Net income (loss) | $(969,463) | $356,536 |
| Basic and diluted earnings (loss) per share | $(0.02) | $0.01 |
| Operating cash flow | $272,637 | $(284,618) |
| Investing cash flow | $(250,000) | $0 |
| Financing cash flow | $19,451 | $0 |
At December 31, 2018, cash was $336,679; working capital was $578,002, down from $1,603,042 a year earlier. Total assets were $855,417, current liabilities $47,975, and stockholders’ equity $407,442. The balance sheet also reported $400,000 of redeemable Series A preferred stock. The filing reports no material capital-expenditure commitments or off-balance-sheet arrangements. No gross-margin figure is provided.
Cash from operations was positive despite the net loss; the reconciliation included $727,496 of proceeds from sales of equity investments. Investing activities included $250,000 disbursed under notes receivable. One $200,000 note to the seller carried 6% interest and was secured by the borrower’s assets; a separate $50,000 note became due after a contemplated acquisition failed to close and was fully reserved as doubtful.
Changes, outlook and risks
- Operating expenses rose 21% to $594,242. Professional fees and general and administrative expenses increased, while compensation and bad-debt expense declined. A $99,412 impairment charge included write-offs related to the brand ambassador arrangement.
- Other expense was $375,221, versus other income of $847,407 in 2017. Investment results included a $278,680 unrealized loss in 2018, compared with a $912,094 unrealized gain in 2017; net realized investment losses were $100,759 and $85,170, respectively.
- The remaining fair-value investment portfolio was $215,528, entirely in Ipsidy, Inc. (IDTY), a biometric technology company. Management said it was actively selling the shares and expected to use proceeds for working capital, NFID development, or acquisitions. The filing identifies this concentration as a risk.
- Management and the auditor cited substantial doubt about the company’s ability to continue as a going concern, given the 2018 loss, accumulated deficit of $1,642,510, and no revenue under the new business plan. Management intended to seek debt or equity financing and warned operations might need to be curtailed if funding was unavailable. Although management also stated existing cash would cover working-capital needs for at least 12 months, it gave no assurance of raising funds or reaching profitability.
- Management reported ineffective disclosure controls and internal control over financial reporting, citing material weaknesses including limited segregation of duties, inadequate system and manual controls, and the CFO’s resignation. The auditors issued unqualified opinions on the financial statements but highlighted the going-concern uncertainty; they did not provide an opinion on internal-control effectiveness.
- Subsequent to year-end, the company entered a marketing and branding consulting agreement requiring an initial $25,000 payment, $5,000 monthly payments beginning April 2019, and 100,000 shares in quarterly installments during 2019.
Important facts for investors to verify
- Confirm the issuer and filing period: the supplied document is Point Capital’s 2018 annual report, not a Silo Pharma filing or a quarterly report.
- Check subsequent evidence of NFID’s launch, product sales, and revenue; the stated second-quarter 2019 launch was an expectation, not reported revenue.
- Assess collectability of the $200,000 secured note, the value and liquidity of IDTY shares, and the company’s access to additional financing.
- Review the going-concern disclosure, preferred-stock redemption and conversion terms, and the potential effect of financing or dilution.
- Track remediation of the disclosed control weaknesses and the costs and obligations under the post-year-end consulting agreement.